← Leaderboards
Beverly L Davidson
University Of Iowa
$40,254,264
Attributed
$43,284,364
Total exposure
36
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,819,913 · 37
By mechanism
P01$14,821,503 · 11
R01$12,546,863 · 6
UH3$6,380,002 · 1
U01$6,298,315 · 1
U19$2,395,329 · 1
RC1$1,929,086 · 2
Top collaborators
- Christopher A Ross5 shared
- Yi Xing5 shared
- Leslie Michels Thompson4 shared
Most similar at University Of Iowa
Same institution · by research overlap
- John F Engelhardt$56,184,900
- Daniel T Infield$442,425
- Hanna E Stevens$4,908,405
- Paul B McCray$33,563,463
- Damian J Krysan$18,418,332
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoGene TherapyVectorBrainIn VitroMouse ModelDesignGenesNeurodegenerative DisordersPhenotypeCellsCell LineProductionAffectDependovirusResearch PersonnelTransfection /Expression VectorNeuronsMediatingGene TransferCystic FibrosisRna InterferencePlasmidsProteins
Grant awards (128)
PROJECT 3: MUCOPOLYSACCHARIDOSIS TYPE 1 (MPS1)$637,518
U19 · FY2025 · NS · contact PI
PROJECT 3: MUCOPOLYSACCHARIDOSIS TYPE 1 (MPS1)$688,528
U19 · FY2024 · NS · contact PI
PROJECT 3: MUCOPOLYSACCHARIDOSIS TYPE 1 (MPS1)$1,069,283
U19 · FY2023 · NS · contact PI
RNAi Therapy for Spinocerebellar Ataxia Type 1$746,997
UH3 · FY2023 · NS · contact PI
Therapeutic APOE2 overexpression for early Alzheimer's disease$1,802,422
U01 · FY2022 · NS · contact PI
RNAi Therapy for Spinocerebellar Ataxia Type 1$1,414,317
UH3 · FY2022 · NS · contact PI
Supplemental Request: Therapeutic APOE2 overexpression for early Alzheimer's disease$1,393,438
U01 · FY2022 · NS · contact PI
Therapeutic APOE2 overexpression for early Alzheimer's disease$1,321,545
U01 · FY2021 · NS · contact PI
Therapeutic APOE2 overexpression for early Alzheimer's disease$99,782
U01 · FY2020 · NS · contact PI
Therapeutic APOE2 overexpression for early Alzheimer's disease$1,681,128
U01 · FY2019 · NS · contact PI
RNAi Therapy for Spinocerebellar Ataxia Type 1$1,548,744
UH3 · FY2019 · NS · contact PI
2019 Lysosomal Diseases Gordon Research Conference and Seminar$10,000
R13 · FY2019 · NS · contact PI
Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease$436,818
R01 · FY2018 · NS
RNAi Therapy for Spinocerebellar Ataxia Type 1$2,142,201
UH3 · FY2017 · NS · contact PI
Genomic and functional analysis of transcriptome changes in Huntington's Disease$589,943
R01 · FY2017 · NS · contact PI
RNAi Therapy for Spinocerebellar Ataxia Type 1$527,743
UH3 · FY2017 · NS · contact PI
Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease$439,061
R01 · FY2017 · NS
RNAi Therapy for Spinocerebellar Ataxia Type 1$1,135,776
UH2 · FY2016 · NS · contact PI
Genomic and functional analysis of transcriptome changes in Huntington's Disease$606,057
R01 · FY2016 · NS · contact PI
Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease$445,378
R01 · FY2016 · NS
Genomic and functional analysis of transcriptome changes in Huntington's Disease$674,688
R01 · FY2015 · NS · contact PI
Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease$465,277
R01 · FY2015 · NS
CAG Triplet Repeat Disorders Gordon Research Conference and Seminar$20,000
R13 · FY2015 · NS · contact PI
Genomic and functional analysis of transcriptome changes in Huntington's Disease$681,033
R01 · FY2014 · NS · contact PI
Next generation gene silencing strategies for Huntington's disease$207,900
R21 · FY2014 · NS · contact PI
Investigating cell-type-specific contribution to JNCL$165,849
R21 · FY2014 · NS · contact PI
Genomic and functional analysis of transcriptome changes in Huntington's Disease$653,528
R01 · FY2013 · NS · contact PI
Vector Core$269,974
P01 · FY2013 · HL · contact PI
Approaches to reducing pulmonary inflammation in CF$269,974
P01 · FY2013 · HL · contact PI
Next generation gene silencing strategies for Huntington's disease$226,500
R21 · FY2013 · NS · contact PI
Vector Core$163,386
P30 · FY2013 · DK · contact PI
Investigating cell-type-specific contribution to JNCL$144,500
R21 · FY2013 · NS · contact PI
Advancing Gene Therapy for Late Infantile Neuronal Ceroid Lipofuscinosis$109,030
R21 · FY2013 · NS · contact PI
Investigating cell-type-specific contribution to JNCL$82,000
R21 · FY2013 · NS · contact PI
Advancing Gene Therapy for Late Infantile Neuronal Ceroid Lipofuscinosis$73,114
R21 · FY2013 · NS · contact PI
Vector Core$283,562
P01 · FY2012 · HL · contact PI
Approaches to reducing pulmonary inflammation in CF$283,562
P01 · FY2012 · HL · contact PI
Epitope targeted AAVS for improved airway delivery$226,500
R21 · FY2012 · HL · contact PI
Advancing Gene Therapy for Late Infantile Neuronal Ceroid Lipofuscinosis$226,500
R21 · FY2012 · NS · contact PI
Vector Core$178,081
P30 · FY2012 · DK · contact PI
Gene Transfer Vector$60,793
P01 · FY2012 · HL · contact PI
RNA aptamers for brain delivery$294,000
R01 · FY2011 · NS · contact PI
Vector Core$282,821
P01 · FY2011 · HL · contact PI
Approaches to reducing pulmonary inflammation in CF$282,820
P01 · FY2011 · HL · contact PI
Gene Transfer Vector$60,793
P01 · FY2011 · HL · contact PI
RNA aptamers for brain delivery$50,000
R01 · FY2011 · NS · contact PI
Translating CNS therapies for the NCLs from rodent models to humans$499,218
RC1 · FY2010 · NS · contact PI
RNA interference therapy for Huntington's disease: studies in non-human primates$493,406
RC1 · FY2010 · NS · contact PI
RNA aptamers for brain delivery$297,000
R01 · FY2010 · NS · contact PI
Vector Core$283,278
P01 · FY2010 · HL · contact PI
Approaches to reducing pulmonary inflammation in CF$283,278
P01 · FY2010 · HL · contact PI
Gene Transfer Vector$60,793
P01 · FY2010 · HL · contact PI
RNAi for Dominant Neurological Disease$1,293,698
P01 · FY2009 · NS · contact PI
Translating CNS therapies for the NCLs from rodent models to humans$496,817
RC1 · FY2009 · NS · contact PI
RNA interference therapy for Huntington's disease: studies in non-human primates$439,645
RC1 · FY2009 · NS · contact PI
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$323,419
R01 · FY2009 · NS · contact PI
RNA aptamers for brain delivery$300,000
R01 · FY2009 · NS · contact PI
RNAi for Huntington's Disease$298,239
P01 · FY2009 · NS · contact PI
Vector Core$288,613
P01 · FY2009 · HL · contact PI
Approaches to reducing pulmonary inflammation in CF$288,612
P01 · FY2009 · HL · contact PI
Vector Core$178,030
P30 · FY2009 · DK · contact PI
miRNA-MEDIATED MODULATION OF NEURAL PROGENITOR CELL FATE$150,000
R21 · FY2009 · DA · contact PI
Core--Vector$149,198
P01 · FY2009 · NS · contact PI
Gene Transfer Vector Core$121,270
P30 · FY2009 · CA · contact PI
RNA aptamers for brain delivery$75,000
R01 · FY2009 · NS · contact PI
RNAi for Dominant Neurological Disease$1,339,352
P01 · FY2008 · NS · contact PI
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$323,419
R01 · FY2008 · NS · contact PI
RNAi for Huntington's Disease$308,639
P01 · FY2008 · NS · contact PI
RNA aptamers for brain delivery$300,000
R01 · FY2008 · NS · contact PI
Gene Transfer Vector$297,471
P01 · FY2008 · HL · contact PI
Core--Gene Transfer$212,459
P01 · FY2008 · HL · contact PI
Core--Vector$154,408
P01 · FY2008 · NS · contact PI
miRNA-MEDIATED MODULATION OF NEURAL PROGENITOR CELL FATE$150,000
R21 · FY2008 · DA · contact PI
RNAi for Dominant Neurological Disease$1,259,989
P01 · FY2007 · NS · contact PI
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$323,419
R01 · FY2007 · NS · contact PI
AAV correction of CNS deficits in an MPS model of LSD$314,678
R01 · FY2007 · HD · contact PI
RNAi for Huntington's Disease$309,187
P01 · FY2007 · NS · contact PI
Core--Gene Transfer$210,514
P01 · FY2007 · HL · contact PI
Core--Vector$154,675
P01 · FY2007 · NS · contact PI
RNAi for Dominant Neurological Disease$82,516
P01 · FY2007 · NS · contact PI
Core--Gene transfer vector$64,157
P01 · FY2007 · HL · contact PI
RNAi FOR DOMINANT NEUROLOGICAL DISEASE PO1$1,261,697
P01 · FY2006 · NS · contact PI
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$333,079
R01 · FY2006 · NS · contact PI
AAV correction of CNS deficits in an MPS model of LSD$324,077
R01 · FY2006 · HD · contact PI
RNAI for Huntington's Disease$272,717
P01 · FY2006 · NS · contact PI
Gene therapy for dominant neurodegenerative diseases$216,051
R01 · FY2006 · HD · contact PI
Core--Vector$136,435
P01 · FY2006 · NS · contact PI
Core B--Gene Transfer$131,655
P01 · FY2006 · HL · contact PI
RNAi FOR DOMINANT NEUROLOGICAL DISEASE$1,298,297
P01 · FY2005 · NS
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$341,094
R01 · FY2005 · NS
AAV correction of CNS deficits in an MPS model of LSD$331,875
R01 · FY2005 · HD
RNAI for Huntington's Disease$269,066
P01 · FY2005 · NS
Gene therapy for dominant neurodegenerative diseases$221,250
R01 · FY2005 · HD
Core--Vector$132,461
P01 · FY2005 · NS
Core B--Gene Transfer$127,820
P01 · FY2005 · HL
Administrative$96,360
P01 · FY2005 · NS
GENE TRANSFER VECTOR CORE$77,602
P30 · FY2005 · CA
UI Initiative for Minority Student Development Program$403,720
R25 · FY2004 · GM
AAV correction of CNS deficits in an MPS model of LSD$331,875
R01 · FY2004 · HD
Gene therapy for dominant neurodegenerative diseases$221,250
R01 · FY2004 · HD
Core B--Gene Transfer$124,098
P01 · FY2004 · HL
AAV correction of CNS deficits in an MPS model of LSD$328,336
R01 · FY2003 · HD
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$277,551
R01 · FY2003 · NS
Gene therapy for dominant neurodegenerative diseases$221,250
R01 · FY2003 · HD
Core--Gene transfer vector$42,983
P01 · FY2003 · HL
UI INITIATIVE FOR MINORITY STUDENT DEVELOPMENT PROGRAM$335,878
R25 · FY2002 · GM
CORE--VECTOR$296,752
P30 · FY2002 · DK
CORE--VECTOR$290,033
P01 · FY2002 · HL
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$269,469
R01 · FY2002 · NS
CORRECTION OF MPS VII IN THE CNS USING ADENOVIRAL VECTOR$262,873
R01 · FY2002 · HD
CORE--GENE TRANSFER VECTOR$233,291
P01 · FY2002 · HL
Gene therapy for dominant neurodegenerative diseases$220,500
R01 · FY2002 · HD
CORE--GENE TRANSFER VECTOR$0
P20 · FY2002 · CA
UI INITIATIVE FOR MINORITY STUDENT DEVELOPMENT PROGRAM$326,407
R25 · FY2001 · GM
CORE--VECTOR$296,752
P30 · FY2001 · DK
CORE--VECTOR$290,033
P01 · FY2001 · HL
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$261,617
R01 · FY2001 · NS
CORRECTION OF MPS VII IN THE CNS USING ADENOVIRAL VECTOR$255,217
R01 · FY2001 · HD
CORE--GENE TRANSFER VECTOR$233,291
P01 · FY2001 · HL
CORE--VECTOR$111,112
P01 · FY2001 · NS
CORE--GENE TRANSFER VECTOR$0
P20 · FY2001 · CA
CORE--VECTOR$272,462
P01 · FY2000 · HL
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$253,998
R01 · FY2000 · NS
CORRECTION OF MPS VII IN THE CNS USING ADENOVIRAL VECTOR$247,783
R01 · FY2000 · HD
CORE--GENE TRANSFER VECTOR$192,770
P01 · FY2000 · HL
CORE--VECTOR$171,547
P01 · FY2000 · NS
CORE--VECTOR$143,268
P30 · FY2000 · DK
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS$35,000
R01 · FY2000 · NS